Refractory Non-Hodgkin Lymphoma Clinical Trials in Philadelphia, Pennsylvania

4 studies are recruiting for refractory non-hodgkin lymphoma in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

    Stage
    Phase 1
    Ages
    1 to 30
    Site
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
    Locations
    21 in total
    Run by
    Children's Oncology Group

    See if you can join NCT04851119 on ClinicalTrials.gov

  2. Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

    This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell ly…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Thomas Jefferson University, Philadelphia, Pennsylvania
    Locations
    35 in total
    Run by
    Lyell Immunopharma, Inc.

    See if you can join NCT05826535 on ClinicalTrials.gov

  3. Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

    This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory)…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania
    Locations
    7 in total
    Run by
    AIDS Malignancy Consortium

    See if you can join NCT05077527 on ClinicalTrials.gov

  4. SynKIR-310 for Relapsed/Refractory B-NHL

    This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    5 in total
    Run by
    Verismo Therapeutics

    See if you can join NCT06544265 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.